Dr. Hayes on the Future of Biomarkers for Breast Cancer
Daniel F. Hayes, MD
Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.
It is important to determine better ways to identify which patients after 5 years of endocrine-therapy should continue it or switch to another form of therapy, explains Hayes.
According to Hayes, liquid biopsies are exciting and might have a role in determining which patients should be left on their current treatment.